Genetic requirement for Mycl and efficacy of RNA Pol I inhibition in mouse models of small cell lung cancer

Genes and Development

Volumn 30, Issue 11, 2016, Pages 1289-1299

  Kim, Dong Wook ^a   Wu, Nan ^b   Kim, Young Chul ^c   Cheng, Pei Feng ^b   Basom, Ryan ^b   Kim, Dongkyoon ^d   Dunn, Colin T ^a   Lee, Anastasia Y ^a   Kim, Keebeom ^a   Lee, Chang Sup ^a   Singh, Andrew ^a   Gazdar, Adi F ^e,f,g   Harris, Chris R ^h,i,j   Eisenman, Robert N ^b   Park, Kwon Sik ^a   MacPherson, David ^b  

^a UNIVERSITY OF VIRGINIA   (United States)

^b Fred Hutchinson Cancer Research Center   (United States)

^c H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^d STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^f UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^g UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^h Raymond and Beverly Sackler Foundation   (United States)

ⁱ RUTGERS CANCER INSTITUTE OF NEW JERSEY   (United States)

^j ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

more..

Author keywords

Neuroendocrine; Oncogene; Progression; Ribosome biogenesis; Transcription factor

Indexed keywords

DNA DIRECTED RNA POLYMERASE; RIBOSOME RNA; BENZOTHIAZOLE DERIVATIVE; CX 5461; ENZYME INHIBITOR; MYC PROTEIN; NAPHTHYRIDINE DERIVATIVE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BIOGENESIS; CANCER INHIBITION; CONTROLLED STUDY; ECTOPIC EXPRESSION; ENZYME INHIBITION; GENE DELETION; IN VIVO STUDY; MOUSE; NEUROSECRETORY CELL; NONHUMAN; ONCOGENE C MYC; ONCOGENE L MYC; PRIORITY JOURNAL; RIBOSOME; RNA SYNTHESIS; SMALL CELL LUNG CANCER; ANIMAL; ANTAGONISTS AND INHIBITORS; DISEASE MODEL; DRUG EFFECTS; ENZYME ACTIVATION; ENZYMOLOGY; GENE SILENCING; GENETICS; LUNG TUMOR; METABOLISM; PATHOPHYSIOLOGY; TRANSGENIC ANIMAL; TUMOR CELL CULTURE; TUMOR VOLUME;

ANIMALS; ANIMALS, GENETICALLY MODIFIED; BENZOTHIAZOLES; DISEASE MODELS, ANIMAL; ENZYME ACTIVATION; ENZYME INHIBITORS; GENE SILENCING; LUNG NEOPLASMS; MICE; NAPHTHYRIDINES; PROTO-ONCOGENE PROTEINS C-MYC; RIBOSOMES; RNA POLYMERASE I; SMALL CELL LUNG CARCINOMA; TUMOR BURDEN; TUMOR CELLS, CULTURED;

EID: 84974605091     PISSN: 08909369     EISSN: 15495477     Source Type: Journal    
DOI: 10.1101/gad.279307.116     Document Type: Article

References (33)

1. Arabi A, Wu S, Ridderstrale K, Bierhoff H, Shiue C, Fatyol K, Fahlen S, Hydbring P, Soderberg O, Grummt I, et al. 2005. c-Myc associates with ribosomal DNA and activates RNA polymerase I transcription. Nat Cell Biol 7: 303–310.
2. Barna M, Pusic A, Zollo O, Costa M, Kondrashov N, Rego E, Rao PH, Ruggero D. 2008. Suppression of Myc oncogenic activity by ribosomal protein haploinsufficiency. Nature 456: 971–975.
3. Barrett J, Birrer MJ, Kato GJ, Dosaka-Akita H, Dang CV. 1992. Activation domains of L-Myc and c-Myc determine their transforming potencies in rat embryo cells. Mol Cell Biol 12: 3130–3137.
4. Bhat M, Robichaud N, Hulea L, Sonenberg N, Pelletier J, Topisirovic I. 2015. Targeting the translation machinery in cancer. Nat Rev Drug Discov 14: 261–278.
5. Birrer MJ, Segal S, DeGreve JS, Kaye F, Sausville EA, Minna JD. 1988. L-myc cooperates with ras to transform primary rat embryo fibroblasts. Mol Cell Biol 8: 2668–2673.
6. Bywater MJ, Poortinga G, Sanij E, Hein N, Peck A, Cullinane C, Wall M, Cluse L, Drygin D, Anderes K, et al. 2012. Inhibition of RNA polymerase I as a therapeutic strategy to promote cancer-specific activation of p53. Cancer Cell 22: 51–65.
7. Cui M, Augert A, Rongione M, Conkrite K, Parazzoli S, Nikitin AY, Ingolia N, Macpherson D. 2014. PTEN is a potent suppressor of small cell lung cancer. Mol Cancer Res 12: 654–659.
8. Dang CV. 2012. MYC on the path to cancer. Cell 149: 22–35.
9. de la Cova C, Abril M, Bellosta P, Gallant P, Johnston LA. 2004. Drosophila myc regulates organ size by inducing cell competition. Cell 117: 107–116.
10. Devlin JR, Hannan KM, Hein N, Cullinane C, Kusnadi E, Ng PY, George AJ, Shortt J, Bywater MJ, Poortinga G, et al. 2016. Combination therapy targeting ribosome biogenesis and mRNA translation synergistically extends survival in MYCdriven lymphoma. Cancer Discov 6: 59–70.
11. Diolaiti D, McFerrin L, Carroll PA, Eisenman RN. 2015. Functional interactions among members of the MAX and MLX transcriptional network during oncogenesis. Biochim Biophys Acta 1849: 484–500.
12. Drygin D, Lin A, Bliesath J, Ho CB, O’Brien SE, Proffitt C, Omori M, Haddach M, Schwaebe MK, Siddiqui-Jain A, et al. 2011. Targeting RNA polymerase I with an oral small molecule CX-5461 inhibits ribosomal RNA synthesis and solid tumor growth. Cancer Res 71: 1418–1430.
13. DuPage M, Dooley AL, Jacks T. 2009. Conditional mouse lung cancer models using adenoviral or lentiviral delivery of Cre recombinase. Nat Protoc 4: 1064–1072.
14. Faber AC, Farago AF, Costa C, Dastur A, Gomez-Caraballo M, Robbins R, Wagner BL, Rideout WM 3rd, Jakubik CT, Ham J, et al. 2015. Assessment of ABT-263 activity across a cancer cell line collection leads to a potent combination therapy for small-cell lung cancer. Proc Natl Acad Sci 112: E1288–E1296.
15. Gazdar AF, Savage TK, Johnson JE, Berns A, Sage J, Linnoila RI, MacPherson D, McFadden DG, Farago A, Jacks T, et al. 2015. The comparative pathology of genetically engineered mouse models for neuroendocrine carcinomas of the lung. J Thorac Oncol 10: 553–564.
16. George J, Lim JS, Jang SJ, Cun Y, Ozretic L, Kong G, Leenders F, Lu X, Fernandez-Cuesta L, Bosco G, et al. 2015. Comprehensive genomic profiles of small cell lung cancer. Nature 524: 47–53.
17. Grandori C, Gomez-Roman N, Felton-Edkins ZA, Ngouenet C, Galloway DA, Eisenman RN, White RJ. 2005. c-Myc binds to human ribosomal DNA and stimulates transcription of rRNA genes by RNA polymerase I. Nat Cell Biol 7: 311–318.
18. Hatton KS, Mahon K, Chin L, Chiu FC, Lee HW, Peng D, Morgenbesser SD, Horner J, DePinho RA. 1996. Expression and activity of L-Myc in normal mouse development. Mol Cell Biol 16: 1794–1804.
19. Huijbers IJ, Bin Ali R, Pritchard C, Cozijnsen M, Kwon MC, Proost N, Song JY, de Vries H, Badhai J, Sutherland K, et al. 2014. Rapid target gene validation in complex cancer mouse models using re-derived embryonic stem cells. EMBO Mol Med 6: 212–225.
20. Johnson BE, Ihde DC, Makuch RW, Gazdar AF, Carney DN, Oie H, Russell E, Nau MM, Minna JD. 1987. myc family oncogene amplification in tumor cell lines established from small cell lung cancer patients and its relationship to clinical status and course. J Clin Invest 79: 1629–1634.
21. Kc W, Satpathy AT, Rapaport AS, Briseno CG, Wu X, Albring JC, Russler-Germain EV, Kretzer NM, Durai V, Persaud SP, et al. 2014. L-Myc expression by dendritic cells is required for optimal T-cell priming. Nature 507: 243–247.
22. McFadden DG, Papagiannakopoulos T, Taylor-Weiner A, Stewart C, Carter SL, Cibulskis K, Bhutkar A, McKenna A, Dooley A, Vernon A, et al. 2014. Genetic and clonal dissection of murine small cell lung carcinoma progression by genome sequencing. Cell 156: 1298–1311.
23. Meuwissen R, Linn SC, Linnoila RI, Zevenhoven J, Mooi WJ, Berns A. 2003. Induction of small cell lung cancer by somatic inactivation of both Trp53 and Rb1 in a conditional mouse model. Cancer Cell 4: 181–189.
24. Moreno E, Basler K. 2004. dMyc transforms cells into super-competitors. Cell 117: 117–129.
25. Nakagawa M, Takizawa N, Narita M, Ichisaka T, Yamanaka S. 2010. Promotion of direct reprogramming by transformation-deficient Myc. Proc Natl Acad Sci 107: 14152–14157.
26. Nau MM, Brooks BJ, Battey J, Sausville E, Gazdar AF, Kirsch IR, McBride OW, Bertness V, Hollis GF, Minna JD. 1985. L-myc, a new myc-related gene amplified and expressed in human small cell lung cancer. Nature 318: 69–73.
27. Romero OA, Torres-Diz M, Pros E, Savola S, Gomez A, Moran S, Saez C, Iwakawa R, Villanueva A, Montuenga LM, et al. 2014. MAX inactivation in small cell lung cancer disrupts MYCSWI/ SNF programs and is synthetic lethal with BRG1. Cancer Discov 4: 292–303.
28. Rudin CM, Durinck S, Stawiski EW, Poirier JT, Modrusan Z, Shames DS, Bergbower EA, Guan Y, Shin J, Guillory J, et al. 2012. Comprehensive genomic analysis identifies SOX2 as a frequently amplified gene in small-cell lung cancer. Nat Genet 44: 1111–1116.
29. Schaffer BE, Park KS, Yiu G, Conklin JF, Lin C, Burkhart DL, Karnezis AN, Sweet-Cordero EA, Sage J. 2010. Loss of p130 accelerates tumor development in a mouse model for human smallcell lung carcinoma. Cancer Res 70: 3877–3883.
30. Sutherland KD, Proost N, Brouns I, Adriaensen D, Song JY, Berns A. 2011. Cell of origin of small cell lung cancer: inactivation of Trp53 and Rb1 in distinct cell types of adult mouse lung. Cancer Cell 19: 754–764.
31. Tarhini A, Kotsakis A, Gooding W, Shuai Y, Petro D, Friedland D, Belani CP, Dacic S, Argiris A. 2010. Phase II study of everolimus (RAD001) in previously treated small cell lung cancer. Clin Cancer Res 16: 5900–5907.
32. van Riggelen J, Yetil A, Felsher DW. 2010. MYC as a regulator of ribosome biogenesis and protein synthesis. Nat Rev Cancer 10: 301–309.
33. Vo BT, Wolf E, Kawauchi D, Gebhardt A, Rehg JE, Finkelstein D, Walz S, Murphy BL, Youn YH, Han YG, et al. 2016. The interaction of Myc with Miz1 defines medulloblastoma subgroup identity. Cancer Cell 29: 5–16.